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Abstract
Objectives The WHO recommends artemisinin-based com-
bination therapies for treatment of uncomplicated falcipa-
rum malaria. At least 15 African countries have adopted
artesunate plus amodiaquine as treatment policy. As no
pharmacokinetic data on this combination have been
published to date, we investigated its pharmacokinetic
interactions and tolerability in healthy volunteers in Africa.
Methods In a randomized, three-phase, cross-over study,
amodiaquine (10 mg/kg) and artesunate (4 mg/kg) were
given as single oral doses to 15 healthy volunteers.
Artesunate was given to all volunteers on day 0. On day
7 they received either amodiaquine or amodiaquine plus
artesunate and the alternative regimen on day 28. The
pharmacokinetics of artesunate and amodiaquine and their
main active metabolites dihydroartemisinin and desethyla-
modiaquine were compared following monotherapy and
combination therapy using analysis of variance.
Results Thirteen volunteers completed the study, and
pharmacokinetic parameters could be determined for twelve
volunteers. When given in combination, the mean AUC
was lower for dihydroartemisinin [ratio 67% (95% CI 51–
88%); P=0.008] and desethylamodiaquine [ratio 65% (95%
CI 46–90%); P=0.015] when compared with monotherapy.
Adverse events of concern occurred in four volunteers
(27%): grade 3 transaminitis (n=1), neutropaenia (n=2),
and hypersensitivity (n=1).
Conclusion The total drug exposure to both drugs was
reduced significantly when they were given in combination.
The clinical significance of these interactions is unclear and
must be studied in malaria patients. The frequency and
nature of adverse events among the healthy volunteers were
of concern, and suggest laboratory monitoring would be





Since Plasmodium falciparum has developed resistance to
almost all anti-malarial drugs, the use of combinations of
effective antimalarials with different mechanisms of action
is required to improve cure rates and delay drug resistance.
The World Health Organisation (WHO) now recommends
treatment of uncomplicated falciparum malaria with one of
several artemisinin-based combination therapies (ACTs),
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Cape Town, South Africaincluding artesunate plus amodiaquine [1]. To date at least
15 African countries have adopted artesunate plus amodia-
quine as first-line malaria treatment policy [2].
Although the limited data available suggest that the
combination of artesunate and amodiaquine is well tolerat-
ed as short-course treatment, there are two safety concerns
that have not yet been fully addressed. Neutropaenia and
hepatitis curtailed the use of amodiaquine as prophylaxis in
the 1980s [3–5]. A recent randomised, controlled trial
comparing treatment with amodiaquine alone or in combi-
nation with artesunate found marked, asymptomatic neu-
tropaenia on day 28 (NCI grade 3–4, absolute neutrophil
counts 306–900 μL
−1)i n6 %o f1 5 3c h i l d r e nw i t h
uncomplicated falciparum malaria, all of whom had normal
baseline absolute neutrophil counts [6]. We have previously
reported a case of hepatitis in this group of volunteers that
developed after the second dose of amodiaquine and was
considered probably related to amodiaquine [7]. A similar
report of delayed-onset asymptomatic hepatitis has been
described in healthy American volunteers who had received
artesunate plus amodiaquine alone followed by artesunate
plus amodiaquine plus efavirenz, resulting in early study
discontinuation [8]. In that study, efavirenz was thought to
have caused an increase in amodiaquine concentrations by
competitive inhibition of the P450 cytochrome enzymes
that metabolise amodiaquine. With the widespread use of
artesunate plus amodiaquine treatment in Africa, these
studies support the need for laboratory monitoring of the
treatment’s safety, particularly if antiretrovirals are used
concomitantly [1].
Pharmacokinetic data are still sparse for amodiaquine.
After oral administration, amodiaquine hydrochloride is
rapidly absorbed and undergoes rapid and extensive
metabolisation to desethylamodiaquine, the main active
metabolite. Amodiaquine has a short elimination half-life
(approximately 5 h), while that for desethylamodiaquine is
much longer (6–18 days) [9, 10].
There are several pharmacokinetic studies on oral artesu-
nate in healthy volunteers and malaria patients that give
broadly consistent results [11, 12]. Artesunate is rapidly
absorbed, rapidly converted to its main active metabolite
dihydroartemisinin and rapidly cleared (elimination half-life
generally <1 h). Dihydroartemisinin has similar pharmaco-
kinetic characteristics but has a slightly longer elimination
half-life. There is wide inter-individual variation in artesu-
nate and dihydroartemisinin pharmacokinetic parameters.
No pharmacokinetic interaction data have yet been
published on amodiaquine when used in combination with
artesunate. In view of the forthcoming widespread use of
this combination in Africa, our study aimed to investigate
potential pharmacokinetic interactions between these anti-
malarials and assess their tolerability in healthy volunteers
in Africa.
Methods
Study subjects and study design
Male or female healthy normal volunteers who provided
written informed consent and met the following criteria
were eligible to participate in the study: aged 18–45 years;
no abnormalities on medical history, clinical examination,
laboratory safety assessment (full blood count, differential
white cell count, routine liver and renal function tests) or
electrocardiogram; and a negative pregnancy test (for
female volunteers). Volunteers were excluded if they were
smokers (>5 cigarettes/day), had taken antimalarials or been
in a malarial area in the preceding 8 weeks, had malaria
parasites on a thick smear, used recreational drugs, or had
ingested any alcohol or any medicines (including over-the-
counter preparations) in the week preceding study com-
mencement.
This was a randomised three-phase crossover study. All
volunteers took artesunate (4 mg/kg as Arsumax, 50 mg
tablets, Sanofi-Aventis), the drug with the shorter elimi-
nation half-life, in the first phase, prior to the administra-
tion of amodiaquine. In the second phase, 7 days later, the
volunteers were randomly allocated to one of two
treatment groups: group 1 received a single oral dose of
artesunate (4 mg/kg) plus amodiaquine (10 mg base/kg as
Camoquin, 200 mg tablets, Parke Davis), and group 2
received a single oral dose of amodiaquine (10 mg/kg)
alone. In phase three, 21 days later, the groups received
the alternative regimen. All trial drugs were given under
direct supervision with 200 ml tap water on an empty
stomach after an overnight fast. No caffeinated drinks
were allowed during the study period. Standardised meals
were offered, commencing with breakfast at 2 h post-dose.
Volunteers in phase one had blood samples collected
before taking artesunate and at 0.25, 0.50, 0.75, 1.0, 1.5,
2, 3, 4, 6, 8 and 12 h after artesunate administration. In
phases two and three (i.e. volunteers receiving artesunate
plus amodiaquine or amodiaquine alone) venous blood
samples were collected pre-dose and at 0.25, 0.5, 0.75, 1,
1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h, and days 4, 5, 7,
10, 14 and 20 post-dose. At each time two 5-ml venous
blood samples were collected in tubes containing sodium
heparin anticoagulant, while three 5-ml samples were
collected at each time point for the first 12 h from those
volunteers receiving both drugs. Each sample was centri-
f u g e dw i t h i n5m i no fc o l l e c t i o na n dt h ep l a s m a
transferred to separate plastic cryotubes and frozen at
−70°C until analysed for artesunate, dihydroartemisinin,
amodiaquine and desethylamodiaquine. Volunteers
remained in the study ward for the first 12 h of each
phase; thereafter specimens were collected at outpatient
visits.
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performed during screening and 6 days after artesunate
administration and 20 days after administration of both
amodiaquine and amodiaquine plus artesunate. A 12-lead
electrocardiogram (ECG) was recorded for each volunteer
during screening and approximately 2 h after each drug
dose. The corrected QT interval (QTc) was calculated by
dividing the QT interval by the square root of the R-R
interval. ECGs were reviewed by C.O. and by a
consultant cardiologist. At follow-up visits, the volunteers
were asked to report any new symptoms. A targeted
physical examination was conducted if indicated. An
adverse event together with its relationship to study drugs
was defined according to the WHO guidelines [13] and
the severity graded using the National Cancer Institute
(NCI) Common Toxicity Criteria [14]. All adverse events
and concomitant medications taken were recorded. Any
significant clinical or laboratory abnormalities or the use of
a concomitant medication with a previously described
interaction resulted in the volunteer being withdrawn from
the study.
Ethical approval
This clinical study was conducted in accordance with the
principles laid down by the World Health Assembly of
1975 on Ethics in Human Experimentation and the Helsinki
Declaration. The study adhered to the standards established
for good clinical practice. The protocol was approved by
the University of Cape Town Research Ethics Committee
and the WHO Secretariat Committee for Research Involv-
ing Human Subjects (SCRIHS). Each volunteer was
informed of the objectives, nature and possible risks of
the trial. Written informed consent was obtained from every
volunteer participating in the study. The volunteers were
informed that they were free to withdraw consent at any
time.
Drug assays
Artesunate and dihydroartemisinin concentrations in plasma
were analysed using the method of Batty and colleagues
[15] with minor modifications. Solid-phase extraction of
samples was performed using Bond-Elut phenyl extraction
cartridges (Varian, Harbour City, CA, USA). After washing
the column with 2 ml of water, samples were eluted from
the column with 1.5 ml of acetonitrile, which was then
evaporated to dryness under nitrogen. Samples were
reconstituted in 100 μl of mobile phase (45% acetonitrile,
0.05 M acetic acid, pH 6.0), and 50 μl was injected onto the
column. HPLC was carried out on a Symmetry C 8, 5 μm,
15 cm×4.6 mm HPLC column (Waters, Milford, MA,
USA) using a Waters 600 pump and WISP 712 auto-
sampler. The post-column reagent (1.2 M KOH in 90%
methanol) was introduced using a Waters reagent delivery
module and the mixture passed through a 1-ml reaction coil
(Waters) kept at 69°C. Detection was at 290 nm using a
Waters 484 Tunable Absorbance Detector, which produced
a linear response over the range of the standard curve (20–
1,000 ng/ml). Quality control samples of 15, 75 and
150 ng/ml for artesunate and 75, 450 and 750 ng/ml for
DHA were included in each run. Within- and between-day
coefficients of variation were below 14%. The lower limit
of quantification was 24 ng/ml for both artesunate and
dihydroartemisinin.
Amodiaquine and desethylamodiaquine were analysed
by LC mass spectrometry using an Agilent 1100 Series LC/
MS system. Protein was precipitated from plasma samples
(200 ul) using three volumes of acetonitrile. Supernatant
(5 μl) was injected onto the HPLC. Chromatography was
carried out using a 50×4.6 mm C18 Xterra column
(Waters). The mobile phase comprised 75% acetonitrile,
0.02 M ammonia, pH 10.2. The extracted ion for
amodiaquine was m/z 356 and for desethylamodiaquine
m/z 328. The calibration curve for amodiaquine was linear
in the range 5–100 ng/ml and for desethylamodiaquine in
the range 5–400 ng/ml. Quality control samples of 25, 75
and 250 ng/ml were used for desethylamodiaquine and 2.5,
7.5 and 25 ng/ml for amodiaquine. Within- and between-
day coefficients of variation were below 12%. The lower
limit of quantification was 5 ng/ml for both amodiaquine
and desethylamodiaquine.
Statistical analysis
Pharmacokinetic parameters were calculated from the
artesunate, dihydroartemisinin, amodiaquine and desethyla-
modiaquine concentration profiles using WinNonLin, ver-
sion 3.3 (Pharsight), with concentrations outside the
specified limits of quantification regarded as missing
values. Clearance (Cl) was calculated as 0.693 × Vd/T1/2
where Vd is the apparent volume of distribution and T1/2 is
the elimination half-life. Because there was no intravenous
comparator arm in this study, equivalent bioavailability was
assumed for comparisons of apparent volume of distribu-
tion (Vd/f) and clearance (Cl/f), where f is the oral
bioavailability or fraction of the drug absorbed (unknown).
All four compounds were first analysed separately.
Because both artesunate and dihydroartemisinin are highly
parasiticidal in malaria patients, the pharmacokinetic
parameters associated with therapeutic response [area under
the plasma concentration time curve (AUC) and maximum
clearance (Cmax)] are also reported together as dihydroarte-
misinin equivalents, defined as the sum of the measured
dihydroartemisinin concentrations plus the artesunate con-
centration converted to dihydroartemisinin equivalents
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dihydroartemisinin respectively) [16, 17]. As amodiaquine
undergoes a rapid and extensive conversion to its active
metabolite, desethylamodiaquine was considered the pri-
mary analyte [9, 10, 18].
The pharmacokinetic parameters following administra-
tion of artesunate and amodiaquine alone and in combi-
nation were compared using Stata, version 9.0 [Stata,
College Station, TX, USA]. Data were log-transformed
a n dt h e nc o m p a r e du s i n gt h ea n a l y s i so fv a r i a n c e
(ANOVA) for a cross-over design to take into account
the repeated measures by study subject, treatment period
and treatment groups and, for amodiaquine and desethy-
lamodiaquine, a sequence effect. The treatment effects
generated from the ANOVA were exponentiated in order
to express comparisons between monotherapy and combi-
nation therapy as a ratio. Any apparent discrepancies
between the difference in the group means and these ratios
are due to the fact that the ratios are based on the within-
patient differences in log-transformed values and not the
group arithmetic means. Given the multiple testing,
statistical significance of results should be interpreted
with caution.
For the safety analysis, means and 95% confidence
intervals (95% CI) for each haematological parameter
(haemoglobin, haematocrit, platelets, white cell count,
absolute lymphocyte and neutrophil count) were calculated
at baseline and at the end of each treatment phase. Changes
in these values from baseline were determined using a
mixed effect regression model that took into account
repeated measures within-patient and were adjusted for
the period and period-treatment interaction effects.
Results
Subject demographics
Nineteen volunteers were screened; two were excluded
because of neutropaenia and two withdrew consent. Fifteen
healthy normal volunteers (10 male, 5 female) entered the
study with a mean age, weight and height of 24.4 years,
67.3 kg and 171 cm, respectively. The mean dose of
amodiaquine was 10.72 mg/kg and that of artesunate was
4.26 mg/kg. Safety analysis included all 15 volunteers; only
data from the 13 volunteers who completed the study were
included in the pharmacokinetic analyses. A female
volunteer was withdrawn due to a new prescription of
fluoxetine for depression, as this drug could potentially
interact with artesunate and amodiaquine by inhibiting
cytochrome P450 enzymes. One male volunteer was
withdrawn due to a possible hypersensitivity reaction on
his first exposure to amodiaquine.
Pharmacokinetic parameters
Effect of amodiaquine on artesunate pharmacokinetic
parameters
Data were analysed using a non-compartmental model.
Figure 1a shows the mean plasma concentration time
curves of artesunate and dihydroartemisinin following
administration of artesunate alone and artesunate plus
amodiaquine. The AUC, Cmax a n dt i m et oC max (Tmax)o f
artesunate were similar following monotherapy and com-
bination therapy (Table 1). Figure 2a illustrates the impact
of adding amodiaquine on the dihydroartemisinin AUC.
Following the combination therapy, dihydroartemisinin
AUC was lower [ratio 67% (95% CI 51–88%); P=0.008],
Cmax was lower [ratio 51% (95% CI 33–78%); P=0.005],
T1/2 was longer [ratio 157% (95% CI 115–213%); P=
0.008] and Vd was larger [ratio 192% (95% CI 133–







































































Fig. 1 Profiles of mean drug concentrations over time following
monotherapy (mono) and combination (combo) therapy for a
artesunate (AS) and dihydroartemisinin (DHA) and b amodiaquine
(AQ) and desethylamodiaquine (DEAQ)
686 Eur J Clin Pharmacol (2008) 64:683–690therapy (Table 1). These ratios have been adjusted for
repeated measures by subject and period effects. As a
measure of the total exposure to artemisinin derivatives,
the Cmax and AUC of the combined DHA-equivalents
were also analysed and found to be lower following
combination therapy [Cmax ratio 51% (95% CI 32–84%),
P=0.011; AUC ratio 72% (95% CI 54–95%), P=0.023]
when compared with monotherapy. Cl and Tmax of
dihydroartemisinin were similar when monotherapy and
combination therapy were administered (Table 1).
Effect of artesunate on amodiaquine pharmacokinetic
parameters
Amodiaquine samples for one volunteer were missing.
Figure 1b shows the mean plasma concentrations of
desethylamodiaquine over time following administration
of amodiaquine alone and in combination. Figure 2b
illustrates the impact of artesunate on the desethylamodia-
quine AUC. The volunteer (subject A) who had the highest
observed AUC for desethylamodiaquine following combi-
nation therapy [29,504 ng·h/ml compared with the mean of
8,437 (95% CI 5,744–11,131) ng·h/ml] was excluded from
the pharmacokinetic analyses of desethylamodiaquine, as
this was an extreme outlier and influential observation
(Fig. 2b; Fig. 3).
The impact of adding artesunate to amodiaquine on the
pharmacokinetic parameters of amodiaquine and desethy-
lamodiaquine is reported for the remaining 11 volunteers.
The pharmacokinetic parameters of amodiaquine were
similar when administered as monotherapy or in combina-
tion with artesunate (Table 2). The desethylamodiaquine
AUC is lower [ratio 65% (95% CI 46–90%); P=0.015],
Tmax shorter [ratio 60% (95% CI 45–80%); P=0.003] and
clearance more rapid [ratio 164% (95% CI 112–243%); P=
0.016] when amodiaquine was administered in combination
with artesunate rather than as monotherapy (Table 2). There
was a trend towards a lower day 7 concentration of
desethylamodiaquine [ratio 56% (95% CI 30–104%); P=
0.064] when amodiaquine was administered in combination
(Fig. 3). These ratios have been adjusted for repeated
measures by subject, period and sequence effects. The Vd
and Cmax were not significantly different when monother-
apy and combination therapy were administered.
Safety
Twenty-nine adverse events were reported over the course
of the study by 10 (67%) of the 15 volunteers. The
frequency of adverse events was similar across all three
treatment arms (P>0.10): 4/15 (27%) following artesunate
alone, 8/15 (53%) following amodiaquine alone, and 5/15
(33%) following the combination. All adverse events were
consistent with the product information available, resolved
spontaneously and, except for the transaminitis (see below)
were mild or moderate in intensity.
A case of asymptomatic, prolonged, severe transamini-
tis (NCI grade 3, AST 5–20× upper limit of normal) that
developed after phase 3 of the study has been previously
published [7]. This was considered to be probably related
to amodiaquine, rather than artesunate, before the phar-
macokinetic results were available. The subsequent find-
ing that this volunteer had the highest measured
desethylamodiaquine AUC following the administration
of artesunate plus amodiaquine [29,504 ng·h/ml compared
with the combination therapy mean of 8,437 (95% CI
Table 1 Pharmacokinetic parameters for artesunate and dihydroartemisinin when artesunate was administered alone and with amodiaquine (ACT)
AUC (ng·h/ml) Cmax (ng/ml) Tmax (h) T1/2 (h) Vd/f (l) Cl/f (l/min)
Artesunate
AS alone (mean±SD) 206.4±135.5 231.8±155.0 0.62±0.28 NA NA NA
ACT (mean±SD) 183.3±146.5 141.6±117.5 0.86±0.67 NA NA NA
ACT-to-monotherapy ratio (%)
(mean, 95% CI)
36 (8–173) 25 (6–105) 125 (76–202) NA NA NA
Significance (ANOVA) 0.18 0.057 0.33
Dihydroartemisinin
AS alone (mean±SD) 2,044.4±564.2 844.5±309.4 1.10±0.95 1.46±0.48 4.89±1.67 2.46±0.86
ACT (mean±SD) 1,410.5±543.6 446.2±239.5 2.08±1.72 2.20±0.85 9.68±4.16 3.08±0.82
ACT-to-monotherapy ratio (%)
(mean, 95% CI)
67 (51–88) 51 (33–78) 165 (82–334) 157 (115–213) 192 (133–275) 122 (96–156)
Significance (ANOVA) 0.008 0.005 0.15 0.008 0.003 0.097
Treatment effects generated from the ANOVA were exponentiated to express within-subject comparisons between monotherapy and combination
therapy as a ratio, adjusted for period effects
AUC Area under the plasma concentration time curve, Cmax maximum concentration, Tmax time to Cmax, T1/2 elimination half-life, Vd volume of
distribution, f oral bioavailability or fraction of the drug absorbed, Cl clearance, AS artesunate, SD standard deviation, CI confidence interval, NA
not available (too few detectable concentrations for calculation of T1/2, Cl, Vd)
Eur J Clin Pharmacol (2008) 64:683–690 6875,744–11,131) ng·h/ml] strengthened this assessment.
There were no liver function abnormalities detected in
any other volunteers. No renal or electrolyte abnormalities
were detected in any volunteers.
Significant haematological changes were confined to the
white cell counts. During phase 2 of the study, two volunteers
(one following amodiaquine alone, one following the combi-
nation) developed asymptomatic, NCI grade 1 leucopaenia (3
to <4 × 10
9/L) and either a grade 1 (1.5 to <2 ×10
9/L) or
grade 2 (1 to <1.5 × 10
9/L) neutropaenia. None of the other
observed changes in haematological parameters were outside
the normal range.
There were no significant changes following treatment
seen on the ECGs; the mean (95% CI) QTc interval was
398 (390–406) ms at screening, 401 (393–409) ms
following artesunate alone, 400 (385–414) ms following
amodiaquine alone and 412 (400–424) ms following the
combination. In two patients, the prolongation following
treatment with amodiaquine or artesunate plus amodiaquine
was considered of borderline clinical significance.
Discussion
The pharmacokinetic analyses in this randomised, cross-
over study showed statistically significant pharmacokinetic
interactions resulting in reductions in the AUC of both
dihydroartemisinin and desethylamodiaquine when artesu-
nate and amodiaquine were given in combination to healthy
volunteers. Of further concern is that one healthy volunteer
failed to reach quantifiable concentration of both artesunate
and dihydroartemisinin throughout the initial 12 h. There is
insufficient evidence currently available to explain the basis
of these interactions.
The clinical significance of our findings is unclear
because we studied healthy volunteers. In one study
comparing pharmacokinetic parameters of dihydroartemisi-
nin in patients and volunteers, patients had a significantly
higher Cmax (1,948 vs. 1,192 nmol/l) and AUC0–12 (4,024
vs. 1,763 nmol·h/l), while their Vd and Cl were both lower.
The Tmax and terminal elimination half-life of the patients
were similar to those of the volunteers [19]. Desethylamo-
diaquine pharmacokinetic parameters in malaria-infected
adults in Africa [20] and children with acute malaria in
Papua New Guinea [21] were similar to those of normal
volunteers.
In artemisinin-based combination therapy, the artemisi-
nin is given to kill most of the parasites quickly, while the
longer-acting partner drug (e.g. amodiaquine) is given to
kill the residual parasites. For an antimalarial with a long
elimination half-life like desethylamodiaquine, the key






















































-.2 AQ AS+AQ 1.2
Subject by treatment
Fig. 3 Stick plot comparing individual patients. Day 7 concentrations
of desethylamodiaquine when amodiaquine was administered as
monotherapy and in combination with artesunate. (Note: volunteer A
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C
Fig. 2 Stick plot comparing individual patient AUCs following
monotherapy and combination therapy of a dihydroartemisinin
(DHA) and b desethylamodiaquine (DEAQ). (Note: volunteer A was
excluded from the statistical analyses)
688 Eur J Clin Pharmacol (2008) 64:683–690which is a useful predictor of therapeutic response as it
captures both the drug concentration and the duration of
exposure [22, 23]. For such drugs the antimalarial concen-
tration on day 7 is strongly correlated with AUC, and thus
treatment response [23]. An association of desethylamodia-
quine concentration on day 7 and amodiaquine treatment
response has been found in children with uncomplicated
falciparum malaria [18]. In our study, the AUC (and
probably the day 7 desethylamodiaquine concentration)
was reduced following the artemisinin-based combination;
this may result in reduced parasite killing, particularly in
areas where there is reduced amodiaquine sensitivity.
Although there is a linear relationship between amodia-
quine dose and the desethylamodiaquine AUC [24], the
wide inter-individual variability in desethylamodiaquine
levels (five-fold in our study), and the consequent potential
for drug-induced toxicity, could preclude increasing the
amodiaquine dose to compensate for the lower desethyla-
modiaquine AUC observed following co-administration
with artesunate.
Extensive clinical trial data show that artesunate plus
amodiaquine is more effective (at clearing parasitaemia and
preventing recrudescence) than amodiaquine alone [1, 6].
Therefore, if reductions in the Cmax and AUC of desethy-
lamodiaquine and dihydroartemisinin occur in patients, the
negative effect on parasite killing may become clinically
insignificant due to the additive (or possibly synergistic)
parasiticidal effects of the combination. However, this may
only apply to areas where the level of amodiaquine
resistance is low. Although clinically significant resistance
to the artemisinins has not yet been documented, amodia-
quine resistance is well documented and this is probably the
principal explanation for low artesunate plus amodiaquine
cure rates observed in a number of African countries [1, 6].
Despite our small sample size, we detected the well-
known amodiaquine-related adverse drug reactions. Clini-
cally important adverse events were reported by a quarter of
these volunteers, even though all were healthy and only two
doses were administered 3 weeks apart (rather than the
daily administration for 3 days recommended for malaria
treatment). When the artesunate plus amodiaquine combina-
tion becomes widely used, monitoring of liver function tests
and haematological parameters are warranted to define these
risks in malaria patients, particularly in patients at special risk
such as those at the extremes of age, withHIVco-infection or
malnutrition [1]. However, the feasibility of this recommen-
dation outside of the research setting is of concern.
To conclude, the total exposure to the main active
metabolites of both artesunate and amodiaquine was
significantly reduced when administered in combination to
healthy African volunteers; this might be important clini-
cally. However, because cure rates with this combination
are generally higher than with amodiaquine monotherapy,
artesunate and amodiaquine could remain in the armamen-
tarium of drugs used to combat falciparum malaria,
provided efficacy continues to be monitored and adequate
safety precautions can be taken. Further pharmacokinetic
research on artesunate plus amodiaquine, when adminis-
tered concurrently or as a fixed dose combination, is
urgently required in patients with malaria to establish the
extent and clinical significance of these pharmacokinetic
interactions.
Table 2 Pharmacokinetic parameters for desethylamodiaquine (DEAQ) when amodiaquine was administered alone and with artesunate (ACT)
AUC
(ng·h/ml)
Cmax (ng/ml) Tmax (h) [Day 7]
(ng/ml)
T1/2 (h) Vd/f (l) Cl/f (l/min)
Amodiaquine
AQ alone (mean±SD) 162.4±101.4 29.2±10.9 2.32±1.16 NA 5.3±4.1 361.0±128.3 69±59
ACT (mean±SD) 108.5±56.0 22.7±9.0 2.18±1.61 NA 3.9±1.2 467.7±180.5 86±26
ACT-to-monotherapy (%)
(mean, 95% CI)
77 (47–127) 78 (58–103) 92 (57–147) NA 74 (29–189) 128 (93–175) 172 (84–357)
Significance (ANOVA) 0.27 0.07 0.68 0.44 0.11 0.11
Desethylamodiaquine
AQ alone (mean±SD) 12,041±
3,480
268.7±70.8 3.68±1.85 19.4±7.3 240.8±146.9 234.1±97.5 768±252
ACT (mean±SD) 8,437±4,009 301.4±166.1 2.18±1.03 13.3±7.3 136.9±83.8 210.8±92.9 1,330±735
ACT-to-monotherapy
ratio (%) (mean, 95% CI)
65 (46–90) 103 (73–147) 60 (45–80) 56 (30–104) 53 (25–111) 88 (51–149) 164 (112–
243)
Significance (ANOVA) 0.015 0.82 0.003 0.064 0.08 0.58 0.016
Treatment effects generated from the ANOVA have been exponentiated to express within-subject comparisons between monotherapy and
combination therapy as a ratio, adjusted for period and sequence effects
AUC Area under the plasma concentration time curve, Cmax maximum concentration, Tmax time to Cmax, [Day 7] day 7 concentration, T1/2
elimination half-life, Vd apparent volume of distribution, f oral bioavailability or fraction of the drug absorbed, Cl clearance, AQ amodiaquine, SD
standard deviation, CI confidence interval, NA not available (as too few patients had quantifiable amodiaquine concentrations)
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